Font Size: a A A

Research On The Impact Mechanism Of Executive Heterogeneity On Dual Innovation

Posted on:2021-04-13Degree:MasterType:Thesis
Country:ChinaCandidate:W Q WangFull Text:PDF
GTID:2439330602494349Subject:Business Administration
Abstract/Summary:PDF Full Text Request
As China accelerates the process of building an innovation-oriented country,the advantages of companies with strong innovation capabilities are gradually emerging.As an industry that requires strong R&D capabilities,the biopharmaceutical industry should adapt to the external environment and gradually strengthen its own innovation capabilities.However,compared with the well-known pharmaceutical companies in developed countries,the R&D level of most domestic biopharmaceutical companies still falls behind.This article will take the decision-making behavior of enterprises' R&D investment as the point of penetration,and explore the causes and consequences of R&D investment of biopharmaceutical companies.R&D investment requires a series of strategic support.As the main decision makers of the corporation strategy,the senior management team plays a key role in guiding the development of the corporation.The senior management team tends to make different strategic choices because of their differences in age,gender,education background,career background,and overseas background.The most direct consequence of large R&D investment by enterprises is the increase in the number of patents,that is,the increase in the output of exploratory innovation and exploitative innovation.Therefore,this article will deeply explore the impact mechanism of executive heterogeneity to the dual innovation,and provide certain guidance for the optimization of management teams and the increase of innovation output in related industries.This article first defines the concepts of executive heterogeneity,R&D intensity,and dual innovation,and determines the scope of the study.Then we arrange related theories such as Upper Echelons Theory,Resource-based View,and technology innovation,and discuss related theoretical backgrounds.Then,based on the"characteristic-behavioral decision-result" ideological path,using research and development intensity as an intermediate variable,explore the impact of executive heterogeneity on corporate dual innovation and its internal impact mechanism,and conduct relevant literature reviews.The results of this study show that gender heterogeneity,age heterogeneity and enterprise exploitative innovation,exploratory innovation are negatively related;Overseas background heterogeneity and education heterogeneity have no significant correlation with exploititive innovation,and there is a significant positive correlation with exploratory innovation;career heterogeneity has positive correlation with exploitative innovation and exploratory innovation,respectively;the two relationship-oriented types,including gender heterogeneity and age heterogeneity,have a significant negative correlation with R&D intensity;overseas background heterogeneity,education background heterogeneity,and career background heterogeneity are two task-oriented heterogeneity,which have a significant positive correlation with R&D intensity;R&D intensity has partial mediating effects between gender heterogeneity,age heterogeneity,education heterogeneity,overseas background heterogeneity,career heterogeneity and exploratory innovation;The mediating effects between gender heterogeneity,age heterogeneity,overseas background heterogeneity,education heterogeneity and career heterogeneity and exploitative innovation have not been verified.
Keywords/Search Tags:executive heterogeneity, medical company, R&D intensity, dual innovation
PDF Full Text Request
Related items